Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant lubricin - Lubris BioPharma/Novartis

Next Previous
Drug Profile

Recombinant lubricin - Lubris BioPharma/Novartis

Alternative Names: ECF 843; lubricin recombinant; Recombinant Human Proteoglycan 4; rh-lubricin; rhPRG-4

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lubris BioPharma
  • Developer Dompe Farmaceutici; Lubris BioPharma; Novartis
  • Class Antirheumatics; Eye disorder therapies; Glycoproteins; Recombinant proteins
  • Mechanism of Action Lubricin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Dry eyes
  • No development reported Osteoarthritis

Most Recent Events

  • 28 May 2025 No recent reports of development identified for preclinical development in Osteoarthritis in USA
  • 27 Sep 2024 Pharmacodynamics data from a preclincal trial in Osteoarthritis presented at the Annual Meeting of the American Society for Bone and Mineral Research 2024 (ASBMR-2024)
  • 10 Jul 2024 Lubris BioPharma plans a phase I/II trial for Ocular graft-versus-host disease (Topical) (NCT06495307)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top